Bajaj Healthcare Limitedrevenue +18.9%, PAT +26.9%, formulations +82%

Bajaj Healthcare's Q2 FY27 call, held on 19 October 2026, reported revenue of ₹175.9 crore, up 18.9%, and profit after tax of ₹14.1 crore, up 26.9%, with EBITDA of ₹32.1 crore at an 18.2% margin.

Formulations grew 82% to ₹41.7 crore after the launch of the anti-seizure drug Cenobamate through eight marketing partners, API exports grew 28.5% to ₹62.6 crore, and domestic API revenue fell to ₹71.6 crore. Together exports and formulations are close to 60% of revenue. The NCLT approved the Genrx Pharmaceuticals acquisition, a peptide plant is due by March 2027 and an oncology API plant from Q2 FY28. Inventory was raised because of West Asia risk, India Ratings upgraded the company to IND A, and management aims for ₹900 crore to ₹1,000 crore of revenue at an 18% to 21% EBITDA margin by FY29.

FY27 growth of 10% to 15% is said to be on track, with operating cash flow above ₹30 crore. No earlier promises were on file for comparison.